#### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Proposed Highly Specialised Technologies Evaluation**

# OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency ID1152

### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Company	General
Orchard Therapeutics (OTL-101)	All Wales Therapeutics and Toxicology     Centre
Patient/carer groups	Allied Health Professionals Federation
Action for Sick Children	Board of Community Health Councils in
Anthony Nolan	Wales
Findacure	British National Formulary
Friends, Families and Travellers	British Society of Blood and Marrow
Genetic Alliance UK	Transplantation
Genetic Disorders UK	Care Quality Commission
Metabolic Support UK	Department of Health, Social Services and
Midaye	Public Safety for Northern Ireland
Muslim Council of Britain	Healthcare Improvement Scotland
National Children's Bureau	Medicines and Healthcare Products
Ocean Somali Community Association	Regulatory Agency
Paveepoint Traveller and Roma Centre	National Association of Primary Care
Primary Immunodeficiency UK	National Pharmacy Association
Purine Metabolic Patients' Association	National Services Division (specialised
South Asian Health Foundation	services in Scotland)
Specialised Healthcare Alliance	NHS Alliance
The National Federation of Gypsy Liaison	NHS Blood and Transplant
Groups	NHS Confederation     Constant Medicines Constant was
The Travellers Movement	Scottish Medicines Consortium
Together for Short Lives	United Kingdom National Screening     Committee
UK Primary Immune-deficiency Patient	Welsh Blood Service
Support	Welsh Government
UK Primary Immunodeficiency Network	Welsh Health Specialised Services
Professional groups	Committee
Association of Genetic Nurses &	Committee
Counsellors	Possible comparator companies
Association of Paediatric Emergency	Orchard Therapeutics (Strimvelis)
Medicine	,
British Association of Neurologists	Relevant research groups
British Inherited Metabolic Disease Group	Cell and Gene Therapy Catapult
British Society for Gene and Cell Therapy	Cochrane Cystic Fibrosis and Genetic
British Society for Genetic Medicine	Disorders Group
British Society for Human Genetics	Gene and Cell Therapy Group - UCL
British Transplantation Society	Medical Research Council - Human
Genomics England	Genetics Unit
Royal College of General Practitioners	MRC Clinical Trials Unit
Royal College of Nursing	National Institute for Health Research

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Royal College of Paediatrics &amp; Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society for the Study of Inborn Errors of Metabolism</li> <li>UK Clinical Pharmacy Association</li> <li>UK Genetic Testing Network</li> </ul>	Associated Public Health Groups  Public Health England  Public Health Wales
<ul> <li>Others</li> <li>Department of Health and Social Care</li> <li>Great Ormond Street Hospital –</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

# <u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.